Encompass Health Named Top SMidCap Pick by TD Cowen
TD Cowen analyst Ryan Langston reiterated Encompass Health (EHC) as a top small- and mid-cap pick after its strong Q2 FY2026 results. Adjusted EBITDA was $348M (+3% vs consensus), revenue $1.597B (+10%), and EPS $1.55. Same-store volume rose 2.8%. EHC raised FY2026 adjusted EBITDA guidance by $15M and authorized a $1B share repurchase.
How this was made
The 30-second read
Why it matters
The core tradable inputs are the Q2 beats, the raised full-year revenue and adjusted EBITDA guidance, and the new $1B repurchase authorization, which can influence valuation and near-term positioning.
Market read
Company-specific guidance and buyback details can drive positioning, but the broader tape is described as slipping slightly with CPI eyed next.
What to watch
Buyback authorization is supportive, but traders may discount it if leverage, reimbursement policy risk, or facility consolidation effects offset volume gains.
Background
TD Cowen analyst Ryan Langston maintained Encompass Health as a top small- and mid-cap pick after strong fiscal 2026 Q2 results.
Ticker impact
Encompass Health beat Q2 adjusted EBITDA and raised full-year 2026 adjusted EBITDA guidance, plus authorized a new $1B share repurchase program.
Mildly positive bias for EHC, with follow-through risk if the market focuses on macro jitters (Hormuz) and CPI timing.
The text includes specific Q2 beats, guidance increases, and buyback authorization, which are actionable fundamentals; however, it is presented as TD Cowen maintaining a top pick, not as a brand-new disclosure event in this article.
Market effects
Reinforces positive read-through for US post-acute care operators on demand, occupancy, and cost control.
Limited, mostly US healthcare equities sentiment.
Low; macro risk is mentioned (Hormuz jitters) but no direct global linkage is provided.
Counterpoint
The article may overstate durability of demand and margin tailwinds, since it also notes headwinds from net supplemental discharge payments.
Key entities
- public_companyEncompass Health Corporation
Reported Q2 fiscal 2026 adjusted EBITDA of $348M, beat consensus, and raised full-year 2026 adjusted EBITDA guidance; authorized a new $1B share repurchase program.
- analyst_firmTD Cowen
Maintained Encompass Health as its top small- and mid-cap pick.
- analystRyan Langston
TD Cowen analyst who reiterated the top-pick stance.
